ABIVAX Société Anonyme (0RA9.L)

EUR 7.35

(-0.34%)

EBITDA Summary of ABIVAX Société Anonyme

  • ABIVAX Société Anonyme's latest annual EBITDA in 2023 was -133.2 Million EUR , down -132.06% from previous year.
  • ABIVAX Société Anonyme's latest quarterly EBITDA in 2024 Q2 was -79.82 Million EUR , down 0.0% from previous quarter.
  • ABIVAX Société Anonyme reported an annual EBITDA of -53.31 Million EUR in 2022, down -8.73% from previous year.
  • ABIVAX Société Anonyme reported an annual EBITDA of -42.19 Million EUR in 2021, down -31.63% from previous year.
  • ABIVAX Société Anonyme reported a quarterly EBITDA of -39.2 Million EUR for 2023 Q2, down 0.0% from previous quarter.
  • ABIVAX Société Anonyme reported a quarterly EBITDA of -90.04 Million EUR for 2023 Q4, down 0.0% from previous quarter.

Annual EBITDA Chart of ABIVAX Société Anonyme (2023 - 2013)

Historical Annual EBITDA of ABIVAX Société Anonyme (2023 - 2013)

Year EBITDA EBITDA Growth
2023 -133.2 Million EUR -132.06%
2022 -53.31 Million EUR -8.73%
2021 -42.19 Million EUR -31.63%
2020 -39.53 Million EUR -19.08%
2019 -33.21 Million EUR -74.36%
2018 -19.22 Million EUR -35.43%
2017 -14.05 Million EUR 22.64%
2016 -17.73 Million EUR -0.28%
2015 -18.11 Million EUR -108.3%
2014 -5 Million EUR -17.95%
2013 -7.37 Million EUR 0.0%

Peer EBITDA Comparison of ABIVAX Société Anonyme

Name EBITDA EBITDA Difference
Boiron SA 80.67 Million EUR 265.107%
Laboratorios Farmaceuticos Rovi, S.A. 238.01 Million EUR 155.965%
Vetoquinol SA 104.58 Million EUR 227.372%
Valneva SE -64.51 Million EUR -106.468%
AB Science S.A. -9.28 Million EUR -1335.266%
Nanobiotix S.A. -34.01 Million EUR -291.566%
PHAXIAM Therapeutics S.A. -22.93 Million EUR -480.929%
Vivoryon Therapeutics N.V. -28.35 Million EUR -369.816%
BioSenic S.A. -6.79 Million EUR -1860.079%
Formycon AG 81.05 Million EUR 264.346%